Research programme: lipid encapsulated methotrexate - LiPlasome Pharma
Latest Information Update: 04 Nov 2017
At a glance
- Originator LiPlasome Pharma
- Class Pterins
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Denmark (IV)
- 25 Feb 2011 Formulation development is ongoing in Denmark
- 05 Apr 2004 Preclinical trials in Cancer in Denmark (IV)